



Ventripoint Strengthens Sales Strategy with Global Expertise to Drive 2025 Growth

For Immediate Release

Toronto, Ontario – January 30, 2025 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) has significantly bolstered its commercial capability with the addition of Karl Pringle to the company's Business Advisory Board to accelerate sales of Ventripoint's AI-powered, heart-scanning technology by hospitals and clinics around the world.

With its proprietary VMS+ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption.

A seasoned global health technology executive, Karl has a proven passion for driving enterprise-level digital transformation initiatives, with extensive experience in the healthcare space. He is adept at building high-performing sales teams that foster vibrant customer and partner ecosystems, enabling accelerated revenue growth. Karl's approach emphasizes accountability, urgency, and customer centricity, ensuring consistent results.

Known for his ability to deliver transformational results, Karl has a remarkable track record of developing and executing strategies that drive hypergrowth. His clear and transparent communication style allows him to energize sales teams, coach effectively, and engage senior stakeholders with compelling value propositions and strategic deal-closing techniques.

"Karl has excelled in global sales, marketing and business development" said Ventripoint's CEO Hugh MacNaught. "With VMS+V4.0 being cleared for sale in multiple markets it is essential that we establish a strong sales trajectory in 2025. Karl's experience and insights will be extremely helpful towards achieving this goal."

Added Pringle: "Ventripoint's VMS+ technology is unique, offering an AI enhancement to echocardiography that provides a portable, inexpensive alternative to MRIs that takes only minutes. For me it is a real market disrupter which is evidenced by its stable of elite customers, and I look forward to engaging with the team to accelerate sales."

For further information, please contact:

Hugh MacNaught

hmacnaught@ventripoint.com

(604) 671-4201



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.